{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:54:28Z","timestamp":1781506468356,"version":"3.54.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00334289"],"award-info":[{"award-number":["RS-2024-00334289"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00439160"],"award-info":[{"award-number":["RS-2024-00439160"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00210407"],"award-info":[{"award-number":["RS-2023-00210407"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-02232977"],"award-info":[{"award-number":["RS-2025-02232977"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003716","name":"Korea Basic Science Institute","doi-asserted-by":"publisher","award":["2023R1A6C101A009"],"award-info":[{"award-number":["2023R1A6C101A009"]}],"id":[{"id":"10.13039\/501100003716","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Costimulation blockade with CTLA-4 Ig (Abatacept) is a widely used strategy to suppress autoreactive T cells; however, its efficacy is often self-limiting due to concurrent depletion of regulatory T cells (Tregs), which depend on CD28 signaling for homeostasis. Here, we demonstrate that costimulation blockade paradoxically potentiates IL-2-driven Treg generation by selectively reprogramming intracellular cytokine signaling. We identified that IL-2 activates STAT3 only in the presence of TCR stimulation, as this pathway requires CD28-mediated PI3K\u2013AKT signaling, which is abrogated by costimulation blockade. Consequently, CTLA-4 Ig uncouples STAT3 activation from IL-2 signaling while sparing STAT5, thereby enhancing TGF-\u03b2\/Smad2\/3 signaling to induce Foxp3 expression. This dual action\u2014sustained STAT5 activation and increased Smad2\/3 signaling\u2014promoted robust Treg generation that ameliorated experimental autoimmune encephalomyelitis (EAE). Furthermore, we confirmed that this synergistic effect is conserved in human T cells from patients with multiple sclerosis (MS) upon CTLA-4 Ig and IL-2 cotreatment. Our findings suggest a strategy to expand the utility of CTLA-4 Ig therapy, providing a mechanistic rationale for combining costimulation blockade with IL-2 to restore immune tolerance in CNS autoimmunity.<\/jats:p>","DOI":"10.1038\/s44321-026-00431-7","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T09:02:39Z","timestamp":1777971759000},"page":"2272-2292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Costimulation loss enhances IL-2-driven Treg generation by PI3K-STAT3 inhibition in CNS autoimmunity"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-663X","authenticated-orcid":false,"given":"Kyung-Ho","family":"Nam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1629-6945","authenticated-orcid":false,"given":"Gil-Ran","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Rim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3588-274X","authenticated-orcid":false,"given":"Young Nam","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2425-6388","authenticated-orcid":false,"given":"Sung-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9482-710X","authenticated-orcid":false,"given":"Je-Min","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"431_CR1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/rheumatology\/keab454","volume":"61","author":"J Aldridge","year":"2022","unstructured":"Aldridge J, Andersson K, Gjertsson I, Hultg\u00e5rd Ekwall A-K, Hallstr\u00f6m M, van Vollenhoven R, Lundell A-C, Rudin A (2022) Blood PD-1+ TFh and CTLA-4+ CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis. Rheumatology 61:1233\u20131242","journal-title":"Rheumatology"},{"key":"431_CR2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/366076a0","volume":"366","author":"M Azuma","year":"1993","unstructured":"Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C (1993) B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76\u201379","journal-title":"Nature"},{"key":"431_CR3","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.4049\/jimmunol.168.10.5070","volume":"168","author":"ML Baroja","year":"2002","unstructured":"Baroja ML, Vijayakrishnan L, Bettelli E, Darlington PJ, Chau TA, Ling V, Collins M, Carreno BM, Madrenas J, Kuchroo VK (2002) Inhibition of CTLA-4 function by the regulatory subunit of serine\/threonine phosphatase 2A. J Immunol 168:5070\u20135078","journal-title":"J Immunol"},{"key":"431_CR4","doi-asserted-by":"crossref","first-page":"15975","DOI":"10.1021\/bi971762i","volume":"36","author":"JD Bradshaw","year":"1997","unstructured":"Bradshaw JD, Lu P, Leytze G, Rodgers J, Schieven GL, Bennett KL, Linsley PS, Kurtz SE (1997) Interaction of the cytoplasmic tail of CTLA-4 (CD152) with a clathrin-associated protein is negatively regulated by tyrosine phosphorylation. Biochemistry 36:15975\u201315982","journal-title":"Biochemistry"},{"key":"431_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2020.100039","volume":"3","author":"S Cavallo","year":"2020","unstructured":"Cavallo S (2020) Immune-mediated genesis of multiple sclerosis. J Transl Autoimmun 3:100039","journal-title":"J Transl Autoimmun"},{"key":"431_CR6","doi-asserted-by":"crossref","first-page":"e83811","DOI":"10.1371\/journal.pone.0083811","volume":"8","author":"K Cerosaletti","year":"2013","unstructured":"Cerosaletti K, Schneider A, Schwedhelm K, Frank I, Tatum M, Wei S, Whalen E, Greenbaum C, Kita M, Buckner J (2013) Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25hi T cells of type 1 diabetic and multiple sclerosis patients. PLoS ONE 8:e83811","journal-title":"PLoS ONE"},{"key":"431_CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4049\/jimmunol.175.1.177","volume":"175","author":"S Chikuma","year":"2005","unstructured":"Chikuma S, Abbas AK, Bluestone JA (2005) B7-independent inhibition of T cells by CTLA-4. J Immunol 175:177\u2013181","journal-title":"J Immunol"},{"key":"431_CR8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nm1385","volume":"12","author":"J-M Choi","year":"2006","unstructured":"Choi J-M, Ahn M-H, Chae W-J, Jung Y-G, Park J-C, Song H-M, Kim Y-E, Shin J-A, Park C-S, Park J-W (2006) Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med 12:574\u2013579","journal-title":"Nat Med"},{"key":"431_CR9","doi-asserted-by":"crossref","first-page":"19875","DOI":"10.1073\/pnas.0805198105","volume":"105","author":"J-M Choi","year":"2008","unstructured":"Choi J-M, Kim S-H, Shin J-H, Gibson T, Yoon B-S, Lee D-H, Lee S-K, Bothwell AL, Lim J-S, Lee S-K (2008) Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis. Proc Natl Acad Sci USA 105:19875\u201319880","journal-title":"Proc Natl Acad Sci USA"},{"key":"431_CR10","doi-asserted-by":"publisher","unstructured":"Confavreux C, Compston A (2009) The natural history of multiple sclerosis. McAlpine\u2019s Mult Scler 183\u2013272. https:\/\/doi.org\/10.1016\/B978-0-443-07271-0.50006-9","DOI":"10.1016\/B978-0-443-07271-0.50006-9"},{"key":"431_CR11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.immuni.2021.03.020","volume":"54","author":"S Dikiy","year":"2021","unstructured":"Dikiy S, Li J, Bai L, Jiang M, Janke L, Zong X, Hao X, Hoyos B, Wang Z-M, Xu B (2021) A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. Immunity 54:931\u2013946","journal-title":"Immunity"},{"key":"431_CR12","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102311","volume":"44","author":"L Fuentes-Rum\u00ed","year":"2020","unstructured":"Fuentes-Rum\u00ed L, Hern\u00e1ndez-Clares R, Carre\u00f3n-Guarnizo E, Valero-L\u00f3pez G, Iniesta-Martinez F, Cabrera-Maqueda JM, Le\u00f3n-Hern\u00e1ndez A, Zamarro-Parra J, Morales-Ortiz A, Meca-Lallana JE (2020) Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. study of two high-dose methylprednisolone schedules. Mult Scler Relat Disord 44:102311","journal-title":"Mult Scler Relat Disord"},{"key":"431_CR13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0898-6568(03)00003-2","volume":"15","author":"MM Fung","year":"2003","unstructured":"Fung MM, Rohwer F, McGuire KL (2003) IL-2 activation of a PI3K-dependent STAT3 serine phosphorylation pathway in primary human T cells. Cell Signal 15:625\u2013636","journal-title":"Cell Signal"},{"key":"431_CR14","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor \u03b1 inhibition. N Engl J Med 353:1114\u20131123","journal-title":"N Engl J Med"},{"key":"431_CR15","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.4049\/jimmunol.1801425","volume":"202","author":"S Glatigny","year":"2019","unstructured":"Glatigny S, H\u00f6llbacher B, Motley SJ, Tan C, Hundhausen C, Buckner JH, Smilek D, Khoury SJ, Ding L, Qin T (2019) Abatacept targets T follicular helper and regulatory T cells, disrupting molecular pathways that regulate their proliferation and maintenance. J Immunol 202:1373\u20131382","journal-title":"J Immunol"},{"key":"431_CR16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R (2016) Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat Med 22:991\u2013993","journal-title":"Nat Med"},{"key":"431_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-023-03236-y","volume":"26","author":"T Iwasaki","year":"2024","unstructured":"Iwasaki T, Watanabe R, Ito H, Fujii T, Ohmura K, Yoshitomi H, Murata K, Murakami K, Onishi A, Tanaka M (2024) Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis. Arthritis Res Ther 26:1","journal-title":"Arthritis Res Ther"},{"key":"431_CR18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2249.2004.02478.x","volume":"136","author":"Jago","year":"2004","unstructured":"Jago, Yates C, Olsen J, Saraiva, C\u00e2mara N, Lechler R, Lombardi G (2004) Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol 136:463\u2013471","journal-title":"Clin Exp Immunol"},{"key":"431_CR19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jneuroim.2013.06.007","volume":"262","author":"A Jamshidian","year":"2013","unstructured":"Jamshidian A, Shaygannejad V, Pourazar A, Zarkesh-Esfahani S-H, Gharagozloo M (2013) Biased Treg\/Th17 balance away from regulatory toward inflammatory phenotype in relapsed multiple sclerosis and its correlation with severity of symptoms. J Neuroimmunol 262:106\u2013112","journal-title":"J Neuroimmunol"},{"key":"431_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1586\/14737175.2016.1123094","volume":"16","author":"DR Jeffery","year":"2016","unstructured":"Jeffery DR, Rammohan KW, Hawker K, Fox E (2016) Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis. Expert Rev Neurotherapeutics 16:31\u201344","journal-title":"Expert Rev Neurotherapeutics"},{"key":"431_CR21","doi-asserted-by":"crossref","first-page":"8705","DOI":"10.1073\/pnas.92.19.8705","volume":"92","author":"JA Johnston","year":"1995","unstructured":"Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, Ortaldo JR, Gupta S, Chen YQ, Giri JD (1995) Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci 92:8705\u20138709","journal-title":"Proc Natl Acad Sci"},{"key":"431_CR22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","volume":"30","author":"SZ Josefowicz","year":"2012","unstructured":"Josefowicz SZ, Lu L-F, Rudensky AY (2012) Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 30:531\u2013564","journal-title":"Annu Rev Immunol"},{"key":"431_CR23","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1128\/MCB.15.6.3049","volume":"15","author":"LM Karnitz","year":"1995","unstructured":"Karnitz LM, Burns LA, Sutor SL, Blenis J, Abraham RT (1995) Interleukin-2 triggers a novel phosphatidylinositol 3-kinase-dependent MEK activation pathway. Mol Cell Biol 15:3049\u20133057","journal-title":"Mol Cell Biol"},{"key":"431_CR24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/39369","volume":"389","author":"M Kawabata","year":"1997","unstructured":"Kawabata M, Heldin N, Heldin C, ten Dijke P (1997) Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389:631\u2013635","journal-title":"Nature"},{"key":"431_CR25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/1352458516662727","volume":"23","author":"SJ Khoury","year":"2017","unstructured":"Khoury SJ, Rochon J, Ding L, Byron M, Ryker K, Tosta P, Gao W, Freedman MS, Arnold DL, Sayre PH et al (2017) ACCLAIM: a randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis. Mult Scler 23:686\u2013695","journal-title":"Mult Scler"},{"key":"431_CR26","volume":"26","author":"D Kim","year":"2026","unstructured":"Kim D, Lee N, Ha S-J (2026) Regulatory T cell heterogeneity in the steady state and tumor. Immune Netw 26:e10","journal-title":"Immune Netw"},{"key":"431_CR27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.14348\/molcells.2022.2056","volume":"45","author":"G-R Kim","year":"2022","unstructured":"Kim G-R, Choi J-M (2022) Current understanding of cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling in T-cell biology and disease therapy. Mol Cells 45:513\u2013521","journal-title":"Mol Cells"},{"key":"431_CR28","volume":"8","author":"G-R Kim","year":"2021","unstructured":"Kim G-R, Kim W-J, Lim S, Lee H-G, Koo J-H, Nam K-H, Kim S-M, Park S-D, Choi J-M (2021a) In vivo induction of regulatory T cells via CTLA-4 signaling peptide to control autoimmune encephalomyelitis and prevent disease relapse. Adv Sci 8:2004973","journal-title":"Adv Sci"},{"key":"431_CR29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4285\/ctr.24.0057","volume":"38","author":"G-R Kim","year":"2024","unstructured":"Kim G-R, Nam K-H, Choi J-M (2024) Belatacept and regulatory T cells in transplantation: synergistic strategies for immune tolerance and graft survival. Clin Transplant Res 38:326\u2013340","journal-title":"Clin Transplant Res"},{"key":"431_CR30","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3390\/pharmaceutics13081134","volume":"13","author":"W-J Kim","year":"2021","unstructured":"Kim W-J, Kim G-R, Cho H-J, Choi J-M (2021b) The cysteine-containing cell-penetrating peptide AP enables efficient macromolecule delivery to T cells and controls autoimmune encephalomyelitis. Pharmaceutics 13:1134","journal-title":"Pharmaceutics"},{"key":"431_CR31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ni.2866","volume":"15","author":"K-F Kong","year":"2014","unstructured":"Kong K-F, Fu G, Zhang Y, Yokosuka T, Casas J, Canonigo-Balancio AJ, Becart S, Kim G, Yates IIIJR, Kronenberg M (2014) Protein kinase C-\u03b7 controls CTLA-4-mediated regulatory T cell function. Nat Immunol 15:465\u2013472","journal-title":"Nat Immunol"},{"key":"431_CR32","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth J, Matsuoka K-I, Kim HT, McDonough SM, Bindra B, Alyea IIIEP, Armand P, Cutler C, Ho VT, Treister NS (2011) Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365:2055\u20132066","journal-title":"N Engl J Med"},{"key":"431_CR33","volume":"2","author":"N Kougkas","year":"2022","unstructured":"Kougkas N, Kruger-Krasagakis S, Papadaki E, Mastorodemos V (2022) Successful treatment of highly active multiple sclerosis and psoriasis exacerbation with natalizumab and secukinumab combination. a case report and literature review. Neuroimmunol Rep 2:100054","journal-title":"Neuroimmunol Rep"},{"key":"431_CR34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","volume":"182","author":"MF Krummel","year":"1995","unstructured":"Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459\u2013465","journal-title":"J Exp Med"},{"key":"431_CR35","volume":"14","author":"W-S Lee","year":"2023","unstructured":"Lee W-S, Nam K-H, Kim JH, Kim W-J, Kim JE, Shin E-C, Kim G-R, Choi J-M (2023) Alleviating psoriatic skin inflammation through augmentation of Treg cells via CTLA-4 signaling peptide. Front Immunol 14:1233514","journal-title":"Front Immunol"},{"key":"431_CR36","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1038\/emm.2017.107","volume":"49","author":"S Lim","year":"2017","unstructured":"Lim S, Ho Sohn J, Koo J-H, Park J-W, Choi J-M (2017) dNP2-ctCTLA-4 inhibits German cockroach extract-induced allergic airway inflammation and hyper-responsiveness via inhibition of Th2 responses. Exp Mol Med 49:e362","journal-title":"Exp Mol Med"},{"key":"431_CR37","volume":"6","author":"S Lim","year":"2015","unstructured":"Lim S, Kim W-J, Kim Y-H, Lee S, Koo J-H, Lee J-A, Yoon H, Kim D-H, Park H-J, Kim H-M (2015) dNP2 is a blood\u2013brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis. Nat Commun 6:8244","journal-title":"Nat Commun"},{"key":"431_CR38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","volume":"174","author":"PS Linsley","year":"1991","unstructured":"Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561\u2013569","journal-title":"J Exp Med"},{"key":"431_CR39","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.aaa1663","volume":"349","author":"B Lo","year":"2015","unstructured":"Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, Zhang Y, Liu Z, Fritz JM, Marsh R (2015) Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349:436\u2013440","journal-title":"Science"},{"key":"431_CR40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-065X.2008.00760.x","volume":"228","author":"U Lorenz","year":"2009","unstructured":"Lorenz U (2009) SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev 228:342\u2013359","journal-title":"Immunol Rev"},{"key":"431_CR41","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1038\/onc.2012.260","volume":"32","author":"R Luwor","year":"2013","unstructured":"Luwor R, Baradaran B, Taylor L, Iaria J, Nheu T, Amiry N, Hovens C, Wang B, Kaye A, Zhu H (2013) Targeting Stat3 and Smad7 to restore TGF-\u03b2 cytostatic regulation of tumor cells in vitro and in vivo. Oncogene 32:2433\u20132441","journal-title":"Oncogene"},{"key":"431_CR42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40261-022-01129-7","volume":"42","author":"CB Malpas","year":"2022","unstructured":"Malpas CB, Roos I, Sharmin S, Buzzard K, Skibina O, Butzkueven H, Kappos L, Patti F, Alroughani R, Horakova D (2022) Multiple sclerosis relapses following cessation of fingolimod. Clin Drug Investig 42:355\u2013364","journal-title":"Clin Drug Investig"},{"key":"431_CR43","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40265-013-0102-7","volume":"73","author":"PL McCormack","year":"2013","unstructured":"McCormack PL (2013) Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis. Drugs 73:1463\u20131481","journal-title":"Drugs"},{"key":"431_CR44","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S, Gladman DD (2017) Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 76:1550\u20131558","journal-title":"Ann Rheum Dis"},{"key":"431_CR45","doi-asserted-by":"crossref","first-page":"12258","DOI":"10.1073\/pnas.1922600117","volume":"117","author":"N Mikami","year":"2020","unstructured":"Mikami N, Kawakami R, Chen KY, Sugimoto A, Ohkura N, Sakaguchi S (2020) Epigenetic conversion of conventional T cells into regulatory T cells by CD28 signal deprivation. Proc Natl Acad Sci USA 117:12258\u201312268","journal-title":"Proc Natl Acad Sci USA"},{"key":"431_CR46","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","volume":"30","author":"M Miyara","year":"2009","unstructured":"Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30:899\u2013911","journal-title":"Immunity"},{"key":"431_CR47","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418773025","volume":"11","author":"P Mulero","year":"2018","unstructured":"Mulero P, Midaglia L, Montalban X (2018) Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord 11:1756286418773025","journal-title":"Ther Adv Neurol Disord"},{"key":"431_CR48","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.2337\/db14-0047","volume":"63","author":"T Orban","year":"2014","unstructured":"Orban T, Beam CA, Xu P, Moore K, Jiang Q, Deng J, Muller S, Gottlieb P, Spain L, Peakman M (2014) Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes 63:3449\u20133457","journal-title":"Diabetes"},{"key":"431_CR49","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1164\/rccm.201207-1205OC","volume":"187","author":"AD Parulekar","year":"2013","unstructured":"Parulekar AD, Boomer JS, Patterson BM, Yin-Declue H, Deppong CM, Wilson BS, Jarjour NN, Castro M, Green JM (2013) A randomized controlled trial to evaluate inhibition of T-cell costimulation in allergen-induced airway inflammation. Am J Respir Crit Care Med 187:494\u2013501","journal-title":"Am J Respir Crit Care Med"},{"key":"431_CR50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jneuroim.2011.09.013","volume":"240","author":"E Peelen","year":"2011","unstructured":"Peelen E, Damoiseaux J, Smolders J, Knippenberg S, Menheere P, Tervaert JWC, Hupperts R, Thewissen M (2011) Th17 expansion in MS patients is counterbalanced by an expanded CD39+ regulatory T cell population during remission but not during relapse. J Neuroimmunol 240:97\u2013103","journal-title":"J Neuroimmunol"},{"key":"431_CR51","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2172-14-34","volume":"14","author":"J Pieper","year":"2013","unstructured":"Pieper J, Herrath J, Raghavan S, Muhammad K, Vollenhoven RV, Malmstr\u00f6m V (2013) CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol 14:34","journal-title":"BMC Immunol"},{"key":"431_CR52","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","volume":"332","author":"OS Qureshi","year":"2011","unstructured":"Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332:600\u2013603","journal-title":"Science"},{"key":"431_CR53","doi-asserted-by":"crossref","unstructured":"Raeber ME, Sahin D, Karakus U, Boyman O (2023) A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. EBioMedicine 90:104539","DOI":"10.1016\/j.ebiom.2023.104539"},{"key":"431_CR54","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1084\/jem.192.2.295","volume":"192","author":"S Read","year":"2000","unstructured":"Read S, Malmstr\u00f6m V, Powrie F (2000) Cytotoxic T lymphocyte\u2013associated antigen 4 plays an essential role in the function of CD25+ CD4+ regulatory cells that control intestinal inflammation. J Exp Med 192:295\u2013302","journal-title":"J Exp Med"},{"key":"431_CR55","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151\u20131164","journal-title":"J Immunol"},{"key":"431_CR56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1074-7613(00)80195-8","volume":"12","author":"B Salomon","year":"2000","unstructured":"Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA (2000) B7\/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431\u2013440","journal-title":"Immunity"},{"key":"431_CR57","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.gastro.2012.04.010","volume":"143","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R (2012) Abatacept for Crohn\u2019s disease and ulcerative colitis. Gastroenterology 143:62\u201369","journal-title":"Gastroenterology"},{"key":"431_CR58","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.4049\/jimmunol.163.4.1868","volume":"163","author":"H Schneider","year":"1999","unstructured":"Schneider H, Martin M, Agarraberes FA, Yin L, Rapoport I, Kirchhausen T, Rudd CE (1999) Cytolytic T lymphocyte-associated antigen-4 and the TCR\u03b6\/CD3 complex, but not CD28, interact with clathrin adaptor complexes AP-1 and AP-2. J Immunol 163:1868\u20131879","journal-title":"J Immunol"},{"key":"431_CR59","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1006\/bbrc.2000.2234","volume":"269","author":"H Schneider","year":"2000","unstructured":"Schneider H, Rudd CE (2000) Tyrosine phosphatase SHP-2 binding to CTLA-4: absence of direct YVKM\/YFIP motif recognition. Biochem Biophys Res Commun 269:279\u2013283","journal-title":"Biochem Biophys Res Commun"},{"key":"431_CR60","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.immuni.2024.02.001","volume":"57","author":"AN Shouse","year":"2024","unstructured":"Shouse AN, LaPorte KM, Malek TR (2024) Interleukin-2 signaling in the regulation of T cell biology in autoimmunity and cancer. Immunity 57:414\u2013428","journal-title":"Immunity"},{"key":"431_CR61","first-page":"856707","volume":"2015","author":"PDM Silva","year":"2015","unstructured":"Silva PDM, Bier J, Paiatto LN, Galdino Albuquerque C, Lopes Souza C, Fernandes LGR, Tamashiro WMDSC, Simioni PU (2015) Tolerogenic dendritic cells on transplantation: immunotherapy based on second signal blockage. J Immunol Res 2015:856707","journal-title":"J Immunol Res"},{"key":"431_CR62","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.192.2.303","volume":"192","author":"T Takahashi","year":"2000","unstructured":"Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Immunologic self-tolerance maintained by CD25+ CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte\u2013associated antigen 4. J Exp Med 192:303\u2013310","journal-title":"J Exp Med"},{"key":"431_CR63","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.4049\/jimmunol.171.7.3348","volume":"171","author":"Q Tang","year":"2003","unstructured":"Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA (2003) Cutting edge: CD28 controls peripheral homeostasis of CD4+ CD25+ regulatory T cells. J Immunol 171:3348\u20133352","journal-title":"J Immunol"},{"key":"431_CR64","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.3390\/cancers13215535","volume":"13","author":"C Tarantelli","year":"2021","unstructured":"Tarantelli C, Argnani L, Zinzani PL, Bertoni F (2021) PI3K\u03b4 inhibitors as immunomodulatory agents for the treatment of lymphoma patients. Cancers 13:5535","journal-title":"Cancers"},{"key":"431_CR65","volume":"10","author":"WA Teft","year":"2009","unstructured":"Teft WA, Chau TA, Madrenas J (2009) Structure-function analysis of the CTLA-4 interaction with PP2A. BMC Immunol 10:23","journal-title":"BMC Immunol"},{"key":"431_CR66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2147\/nedt.2007.3.2.259","volume":"3","author":"A Tselis","year":"2007","unstructured":"Tselis A, Khan O, Lisak RP (2007) Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 3:259\u2013267","journal-title":"Neuropsychiatr Dis Treat"},{"key":"431_CR67","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1074-7613(04)00110-4","volume":"20","author":"L Vijayakrishnan","year":"2004","unstructured":"Vijayakrishnan L, Slavik JM, Ill\u00e9s Z, Greenwald RJ, Rainbow D, Greve B, Peterson LB, Hafler DA, Freeman GJ, Sharpe AH (2004) An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 20:563\u2013575","journal-title":"Immunity"},{"key":"431_CR68","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaci.2008.01.002","volume":"121","author":"F Vincenti","year":"2008","unstructured":"Vincenti F (2008) Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 121:299\u2013306","journal-title":"J Allergy Clin Immunol"},{"key":"431_CR69","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","volume":"374","author":"F Vincenti","year":"2016","unstructured":"Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal M-C, Mondragon-Ramirez GA, Kothari J, Polinsky MS (2016) Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374:333\u2013343","journal-title":"N Engl J Med"},{"key":"431_CR70","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/eji.201445190","volume":"45","author":"I Vogel","year":"2015","unstructured":"Vogel I, Kasran A, Cremer J, Kim YJ, Boon L, Van Gool SW, Ceuppens JL (2015) CD28\/CTLA-4\/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity. Eur J Immunol 45:1832\u20131841","journal-title":"Eur J Immunol"},{"key":"431_CR71","volume":"13","author":"CJ Wang","year":"2022","unstructured":"Wang CJ, Petersone L, Edner NM, Heuts F, Ovcinnikovs V, Ntavli E, Kogimtzis A, Fabri A, Elfaki Y, Houghton LP et al (2022) Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity. Nat Commun 13:6757","journal-title":"Nat Commun"},{"key":"431_CR72","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1038\/onc.2015.446","volume":"35","author":"G Wang","year":"2016","unstructured":"Wang G, Yu Y, Sun C, Liu T, Liang T, Zhan L, Lin X, Feng X-H (2016) STAT3 selectively interacts with Smad3 to antagonize TGF-\u03b2. Oncogene 35:4388\u20134398","journal-title":"Oncogene"},{"key":"431_CR73","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","volume":"39","author":"B Watkins","year":"2021","unstructured":"Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S (2021) Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD. J Clin Oncol 39:1865\u20131877","journal-title":"J Clin Oncol"},{"key":"431_CR74","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.20082824","volume":"206","author":"KE Webster","year":"2009","unstructured":"Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, Grey ST, Sprent J (2009) In vivo expansion of T reg cells with IL-2\u2013mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 206:751\u2013760","journal-title":"J Exp Med"},{"key":"431_CR75","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","volume":"591","author":"R Zappasodi","year":"2021","unstructured":"Zappasodi R, Serganova I, Cohen IJ, Maeda M, Shindo M, Senbabaoglu Y, Watson MJ, Leftin A, Maniyar R, Verma S (2021) CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature 591:652\u2013658","journal-title":"Nature"},{"key":"431_CR76","first-page":"580","volume":"123","author":"R Zhang","year":"2013","unstructured":"Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA (2013) An obligate cell-intrinsic function for CD28 in Tregs. J Clin Investig 123:580\u2013593","journal-title":"J Clin Investig"},{"key":"431_CR77","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/eji.202048794","volume":"51","author":"W Zhang","year":"2021","unstructured":"Zhang W, Liu X, Zhu Y, Liu X, Gu Y, Dai X, Li B (2021) Transcriptional and posttranslational regulation of Th17\/Treg balance in health and disease. Eur J Immunol 51:2137\u20132150","journal-title":"Eur J Immunol"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00431-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00431-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00431-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:32:46Z","timestamp":1781505166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00431-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":77,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,15]]}},"alternative-id":["431"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00431-7","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}